TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23432466
Drug: NRTI-sparing regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI-sparing regimens (e.g., raltegravir plus darunavir/ritonavir)
Study: 23432466
Drug: NRTI-based regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI-based regimens (e.g., tenofovir DF/emtricitabine plus darunavir/ritonavir)
Study: 22108937
Drug: Adenosine 400
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 400 μmol l(‐1) in antegrade cardioplegia
Study: 22108937
Drug: Adenosine 400
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 400 μmol l(‐1) in retrograde cardioplegia
Study: 19158228
Drug: Moderate-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-protein diet (PRO) with 1.6 g/kg/d protein and <170 g/d carbohydrates
Study: 8149056
Drug: History of
Normalized name: BEMOTRIZINOL 0.8 mL in 100 mL / OCTINOXATE 7 mL in 100 mL TOPICAL CREAM [THE HISTORY OF WHOO GONG JIN HYANG HAE YOON SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: History of oral steroid therapy
Study: 23770179
Drug: ETC-1002 40
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 40 mg
Study: 23770179
Drug: ETC-1002 80
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 80 mg
Study: 20185616
Drug: 30 hours
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 hours of robotic-assisted therapy combined with 30 hours of therapist-supervised repetitive task practice (RTP)
Study: 20185616
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (combined therapy and RTP-only)
Study: 18286595
Drug: L-acetylcarnitine (LAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-acetylcarnitine (LAC) 20-50 mg/kg/day
Study: 14583175
Drug: Intensive glycemic
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glycemic treatment aiming at normal HbA1c levels
Study: 10555125
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 without G-CSF
Study: 10555125
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2 with G-CSF
Study: 10555125
Drug: Epirubicin pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin pharmacokinetics
Study: 10555125
Drug: Epirubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75 mg/m2 and Paclitaxel 175 mg/m2
Study: 8724309
Drug: IVIG (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (intravenous immunoglobulin) at a dose between 1.5 and 2.0 g/kg/infusion (100 g maximum) bimonthly for the first 2 months, then monthly for up to 6 months
Study: 8724309
Drug: IVIG (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG (intravenous immunoglobulin) continued in the double-blind phase
Study: 1761450
Drug: Tobramycin dosage
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin dosage regimens determined by a computerized pharmacokinetic predictive program (Group B)
Study: 1761450
Drug: Tobramycin dosage
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin dosage regimens decided by clinicians based on pre-existing protocols (Group A)
Study: 6750609
Drug: Local hyperthermia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local hyperthermia treatment (three 30-min insufflations of humidified air at 43 degrees C at a 2-hr interval)
Study: 30070706
Drug: 20% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sucrose solution applied 4 times per day
Study: 30070706
Drug: 20% sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% sucrose solution applied 8 times per day
Study: 30070706
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0× sucrose treatment)
Study: 26822022
Drug: Daclatasvir (DCV)
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV) for treatment-experienced patients with cirrhosis
Study: 19189088
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of bromazepam
Study: 19189088
Drug: Nasogastric administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasogastric administration of bromazepam
Study: 19189088
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of omeprazole
Study: 19189088
Drug: Nasogastric administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasogastric administration of omeprazole
Study: 19189088
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of paracetamol
Study: 19189088
Drug: Nasogastric administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasogastric administration of paracetamol
Study: 9882032
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg before breakfast (qAM)
Study: 9882032
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg before dinner (qPM)
Study: 9882032
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg before breakfast and dinner (b.d.)
Study: 7924325
Drug: Vaginal rings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h
Study: 7924325
Drug: Vaginal rings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 50 micrograms/24h
Study: 7924325
Drug: Vaginal rings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) at 27 micrograms/24h + transdermal estradiol at 100 micrograms/24h
Study: 7924325
Drug: Vaginal rings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG)
Study: 7924325
Drug: Vaginal rings
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal rings releasing levonorgestrel (L‐NOG) + estradiol (50 or 100 micrograms/24h)
Study: 2803900
Drug: Diphtheria/tetanus vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria/tetanus vaccine
Study: 1169086
Drug: Proximal gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal gastric vagotomy (P.G.V.) without drainage
Study: 1169086
Drug: Proximal gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proximal gastric vagotomy (P.G.V.) with gastrojejunostomy
Study: 14659974
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Pycnogenol for 12 weeks
Study: 11180035
Drug: Intravenous tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tacrolimus (0.015 mg/kg)
Study: 8127015
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no calcitriol treatment)
Study: 28657604
Drug: Fruit fiber
Normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruit fiber consumption (≥8.8 g/day)
Study: 25279689
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise (treadmill training three times per week for 3 months) + vitamin B6 and Ca supplements
Study: 25279689
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 and Ca supplements (control group)
Study: 23865727
Drug: Zabofloxacin hydrochloride
Normalized name: Marbofloxacin
DrugBank: Zabofloxacin (DB12479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabofloxacin hydrochloride 400 mg capsule (DW224a)
Study: 23865727
Drug: Zabofloxacin aspartate
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zabofloxacin aspartate 488 mg tablet (DW224aa)
Study: 22096523
Drug: Internet-based self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based self-management program involving weekly online monitoring of asthma control with self-treatment advice, remote Web communications, and Internet-based information
Study: 19338148
Drug: Jianpi Wenshen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianpi Wenshen Recipe (JPWS) plus chemotherapy
Study: 16782097
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human FSH (rhFSH) at high doses (300 IU on alternate days) for a period of >or=4 months
Study: 27673505
Drug: Naloxone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.25 μg/kg/h)
Study: 18354844
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of natalizumab and interferon beta
Study: 11528361
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 valerate (2 mg) + cyproterone acetate (1 mg)
Study: 11528361
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 (1.5 mg) + oral medroxyprogesterone acetate (5 mg)
Study: 3819804
Drug: High-dose FAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FAC chemotherapy (100% to 260% higher than standard FAC)
Study: 3819804
Drug: Standard-dose FAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose FAC chemotherapy
Study: 3819804
Drug: High-dose FAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose FAC chemotherapy
Study: 29989857
Drug: Standard four‐field
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard four‐field radiation therapy (RT)
Study: 17362050
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy approaches
Study: 17362050
Drug: Newer cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer cytotoxic chemotherapies and biological agents
Study: 9031445
Drug: Warfarin (adjusted-dose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (adjusted-dose, INR 2.0 to 3.0)
Study: 8295037
Drug: Relaxation training
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation training (n = 25, 15-minute daily program at the workplace for 6 months)
Study: 30138685
Drug: Midodrine (15–30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (15–30 mg/day) and albumin (40 g/15 days)
Study: 25124829
Drug: Therapeutic alliance
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alliance and therapist adherence in successful treatments
Study: 25124829
Drug: Therapeutic alliance
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alliance and therapist adherence in treatment failure
Study: 16492320
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% 40 mL injected when nerve stimulation elicited a distal motor response
Study: 16492320
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% 30 mL injected (7 mL to musculocutaneous nerve and 23 mL to median, ulnar or radial nerves)
Study: 10857893
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered when monocytopenia (<150/microl) appeared on days 6 to 8 after chemotherapy (group A)
Study: 10857893
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) administered when neutropenia (<1,000/microl) or leukopenia (<2,000/microl) appeared after chemotherapy (group B)
Study: 8227484
Drug: Iodinated glycerol
Normalized name: iodinated glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodinated glycerol (60 mg four times daily; n = 16)
Study: 30835643
Drug: Drug education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug education (Control)
Study: 29934099
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg thrice daily
Study: 27194199
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER (15-90 mg every 12 hours)
Study: 10618944
Drug: succinylcholine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 0.5 mg kg‐1
Study: 10618944
Drug: succinylcholine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 0.25 mg kg‐1
Study: 7546679
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg amoxicillin every 12 h for 10 days
Study: 7546679
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg amoxicillin every 8 h for 10 days
Study: 7546679
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg amoxicillin at 12 h before surgery
Study: 7546679
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg amoxicillin at 8 h before surgery
Study: 7546679
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg amoxicillin at 6 h before surgery
Study: 7546679
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (acute and chronic sinusitis)
Study: 2020925
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of calcitonin 0.5 mg by intradermic route
Study: 2020925
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of calcitonin 0.5 mg
Study: 7340377
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of morphine in 10 ml of saline (n = 15)
Study: 7340377
Drug: 6‐8 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6‐8 ml of 0.5% bupivacaine with epinephrine (n = 17)
Study: 7340377
Drug: 4‐6 ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐6 ml of 0.5% bupivacaine with epinephrine
Study: 7340377
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of morphine in 10 ml of saline
Study: 28779933
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT‐i)
Study: 25997550
Drug: Generic sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic sildenafil 50 mg film-coated tablets
Study: 25997550
Drug: Viagra® 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viagra® 50 mg film-coated tablets (reference)
Study: 19138577
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (amoxicillin, metronidazole, and omeprazole)
Study: 22004229
Drug: 500 IU
Normalized name: Vitamin E 500 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 IU 1,25 dihydroxy vitamin D3 + calcium combination
Study: 22004229
Drug: Triple DMARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple DMARD therapy + calcium alone
Study: 16980380
Drug: Ramipril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (up to 15 mg per day)
Study: 10397291
Drug: Sialic acid
Normalized name: Ganglioside monosialic acid antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sialic acid concentrations after 5 weeks of treatment
Study: 8862204
Drug: Pamidronate (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (i.v. formulation given monthly)
Study: 8862204
Drug: Oral formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulations of bisphosphonates
Study: 2057277
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (surfactant TA containing surfactant proteins B and C, no SP-A)
Study: 2057277
Drug: Surfactant treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant treatment (surfactant TA)
Study: 30260821
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement with anorganic bovine bone and resorbable collagen barrier (Group A)
Study: 30260821
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement without bone graft (Group B)
Study: 23355182
Drug: Qigong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qigong intervention (5 weekly classes over 5 or 6 weeks of radiotherapy)
Study: 18808446
Drug: Oral delayed-release
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral delayed-release mesalazine (2.4 g/day and 4.8 g/day)
Study: 12545143
Drug: Dipyridamole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (300 mg/d for 3 days)
Study: 11014886
Drug: Intraoral appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoral appliance therapy (ISMAR)
Study: 1592952
Drug: Drugs (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs (specific drugs not mentioned)
Study: 27104984
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri (DSM 17938 and ATCC PTA 5289) lozenges, 2 per day for 3 weeks
Study: 27104984
Drug: Placebo lozenges,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges, 2 per day for 3 weeks
Study: 25180378
Drug: Cranberry capsules
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry capsules (taken twice daily for 12 months)
Study: 25180378
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (taken twice daily for 12 months)
Study: 14693066
Drug: L-OHP +
Normalized name: L-OHP
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-OHP + LV + 5-FU + VP-16 (treatment group)
Study: 11200144
Drug: Infusional fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infusional fluorouracil (5-FU) in combination with cisplatin (Platinol) or newer agents docetaxel (Taxotere) and irinotecan (Camptosar)
Study: 8774625
Drug: Probucol (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (750 mg/day) for at least 30 days prior to PTCA (group P‐1)
Study: 8774625
Drug: Probucol (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (750 mg/day) for less than 14 days prior to PTCA (group P‐2)
Study: 8774625
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/day) for at least 30 days prior to PTCA (group V‐1)
Study: 8774625
Drug: Pravastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10 mg/day) for less than 14 days prior to PTCA (group V‐2)
Study: 1616359
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg twice daily for weeks 0-8, then 400 mg three times a day for weeks 9-24)
Study: 2865187
Drug: Standard-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose oral contraceptive
Study: 27779454
Drug: Lercanidipine hydrochloride
Normalized name: lercanidipine hydrochloride
DrugBank: Lercanidipine (DB00528)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine hydrochloride 10 mg/d
Study: 27779454
Drug: Felodipine sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine sustained-release tablets 5 mg/d
Study: 19146603
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation containing 3.75% glycerol and 1.25% hydrolyzed jojoba esters (K-20W)
Study: 19146603
Drug: Glycerol alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol alone in a standard base skin care lotion
Study: 15380582
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of electron beam radiotherapy (10 Gy)
Study: 3024959
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) administered at a daily dose of 0.5-1 mg intravenously or intramuscularly for 1-4 weeks.
Study: 28384261
Drug: Miltefosine via
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine via caregiver Directly Observed Therapy (cDOT)
Study: 27070526
Drug: Group-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based cognitive behavioral therapy (12 sessions)
Study: 16579084
Drug: Chinese medicines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicines for promoting blood circulation to remove blood stasis
Study: 8584071
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) at a dosage higher than 100 mg/day
Study: 25224595
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy (OC) combined with Caphosol()
Study: 23448434
Drug: Dexmedetomidine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (starting dose, 0.4 μg·kg(‐1) ·h(‐1))
Study: 23448434
Drug: Midazolam (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (starting dose, 0.1 mg·kg(‐1) ·h(‐1))
Study: 21091269
Drug: Clevidipine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevidipine infusion starting at 2 mg/h, doubled every 3 min as needed to a maximum of 32 mg/h, continued for at least 18 h (96 h maximum).